Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.55 - $4.94
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$1.75M
Enterprise Value$12.56M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding3,609,471
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap7.17
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelCatheter Precision’s go-to-market mixes capital sales with per-procedure and service revenue, creating a recurring revenue stream as installed base grows. Over months, per-use and service fees can scale with procedure volumes, improving revenue visibility and long-term cash generation if clinical adoption advances.
Improved Near-term LiquidityThe April financing and new preferred issuances provide immediate runway to fund operations, clinical adoption and commercialization activities. Sustained access to structured capital, while dilutive, reduces near-term solvency risk and permits continued investments that are critical to convert product-market fit into recurring revenues.
Differentiated Non-invasive PlatformVIVO’s non-invasive 3D electrocardiographic mapping targets a structural trend toward less invasive diagnostics. If clinical utility and reimbursement acceptance continue, the technology could yield durable competitive advantage in electrophysiology planning and attract adoption across EP labs, supporting sustained revenue growth.
Bears Say
Sustained Cash BurnMaterial negative operating and free cash flow over the trailing twelve months indicates the business relies on external funding to sustain operations. Persisting cash burn constrains investment in sales, clinical studies and production scale, and raises the likelihood of additional financings that dilute shareholders and stress execution.
Tiny Revenue Base Vs. Large LossesRevenue remains immaterial relative to operating costs, producing extreme negative margins. This structural mismatch implies the current cost base cannot be supported without significant, sustained adoption; absent rapid scale, profitability and margin recovery are unlikely within a 2–6 month horizon.
Dilution And Capital-structure ComplexityReliance on convertible preferred issuances and equity consideration for acquisitions increases potential share dilution and complicates ownership. Approved reverse-split and conversion mechanics give the board flexibility but raise long-term dilution risk and can impair shareholder alignment and financial predictability as future financing needs persist.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.55 and its highest was $4.94 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $1.75M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 33 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 3,609,471 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
Technical Analysis
Ownership Overview
0.52%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---